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Nora FROM DR. MERLE A. SANDE - Progressivehuman immunodeficiencyvirus infection
eventuallyleads to activation and dissemination of a widevarietyof microorganismsnor-
mally held in check by the cellular immune system. Mycobacterium tuberculosis is one
of these pathogens, and the disease caused by it has become a common presenting infec-
tion in the patient with AIDS. Dr. Richard E. Chaisson and Dr. Gary Slutkin have stud-
ied tuberculosis in the United States and worldwide, respectively. In this AIDS Commen-
tary they address the unique nature of this infection, its diagnosis, and its treatment in
the patient with AIDS.
Infection with human immunodeficiency virus
(HIV) ultimately has a profound effect on cell-
mediated immunity and thus increases the risk of
diseases caused by pathogens that are normally held
in check by this defense mechanism. It is therefore
logical to assume that persons with HIV infection
are predisposed to tuberculosis, especially if they
have been previously infected with Mycobacterium
tuberculosis. Presently, there is no definitive substan-
tiation of a causal relation between HIV infection
and tuberculosis, but significant epidemiological in-
formation strongly suggests that this relation exists.
In the United States, since 1984the rate of decline
in tuberculosis cases has halted, and in fact, in 1986
the number of cases of tuberculosis increased by
2.6% from 22 201 to 22 768 [1]. The Division of
Tuberculosis Control of the CDC estimates that in
1985-1987 there were >9000 excess cases of tuber-
culosis over the expected number of cases, had the
rate of decline seen in 1980-1984 continued. The
change in the tuberculosis case-rate is especially
marked in areas where there is a high prevalence of
HIV infection, such as New York City, Florida, and
California. Among United States-born residents of
San Francisco, for example, there was a doubling in
the incidence of tuberculosis from 1982 to 1987 [2].
In 1985 the CDC modified the surveillance defi-
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nition of AIDS to include extrapulmonary tubercu-
losis in any person known to be seropositive for HIV
[3]. Tuberculosis at any site occurs in rv2% of AIDS
cases in San Francisco, 5% of AIDS cases in New
York City, and 10% of AIDS cases in Florida [4, 5].
In addition, Mycobacterium kansasii, a nontuber-
culous mycobacterium that causes disease that is clin-
ically indistinguishable from that caused by M tu-
berculosis, has been reported in a small number of
patients with AIDS. Several recent studies indicate
that the scope of tuberculosis as a complication of
HIV infection may be far greater than previously ap-
preciated. In studies of newly diagnosed cases of
tuberculosis in Miami, Kinshasa (Zaire), and San
Francisco, rv30% of patients were found to be HIV
seropositive, although most lacked other clinical
signs of AIDS [6-8]. As more clinicians perform
serological tests for HIV in patients with tuberculo-
sis, it is likely that a large portion will be found to
have both infections.
Which patients with HIVinfection develop tuber-
culosis? There is no evidence that HIV infection
predisposes patients to acquisition ofM tuberculo-
sis infection. Persons with prior M tuberculosis in-
fection are, however, more likely to develop tuber-
culosis if they are coinfected with HIV. Selwyn and
associates in New York found [9] that 15% of HIV-
seropositive iv drug abusers with a history of a posi-
tive tuberculin skin test developed tuberculosis over
a two-year period, compared with none of a similar
group of HIV-seronegative individuals. The popu-
lations of patients that can be expected to develop
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tuberculosis are those with a high prevalence of coin-
fection with HIV and M. tuberculosis. In developed
countries this includes HIV-seropositive persons who
are immigrants from countries with endemic tuber-
culosis, intravenous drug abusers, poor inner city
residents (particularly members of ethnic minorities),
and close contacts of individuals with tuberculosis.
Screening of these populations with tuberculin skin
tests is an urgent public health priority. In develop-
ing countries the overall prevalence of tuberculous
infections (positive tuberculin tests) may exceed50070,
a fact making it very likely that a substantial propor-
tion of HIV-seropositive persons will have both in-
fections.
What is the clinical presentation? Tuberculosis
in HIV-infected patients, as in other populations, is
primarily a pulmonary infection. Early reports of
AIDS-related tuberculosis focused on the atypical
clinical features found in patients with advanced HIV
disease, particularly extrapulmonary sites of disease,
skin test anergy, and diffuse infiltrates on chest radio-
graphs [10-13]. Subsequent experience has shown
that many HIV-associated cases of tuberculosis oc-
cur earlier in the course of immunosuppression and
have features that are more characteristic of "stan-
dard" tuberculosis. When tuberculosis occurs before
another opportunistic infection, 75070-100% of pa-
tients have pulmonary disease. Tuberculosis occur-
ring after a diagnosis of AIDS has been made is still
most often pulmonary, although extrapulmonary
sites are becoming more commonly involved. Be-
tween 25% and 70lJ,fo of cases of HIV-associated
tuberculosis include an extrapulmonary site of dis-
ease, a finding that fulfills the CDC surveillance
criteria for AIDS. It is likely that extrapulmonary
tuberculosis portends a poorer outcome than does
pulmonary tuberculosis alone, because extrapulmo-
nary cases appear to have a greater degree of immu-
nodeficiency as measured by CD4+ cell counts and
the presence of oral candidiasis.
The symptoms of tuberculosis in HIV-seropositive
patients are similar to those encountered in other pa-
tients. Fever and night sweats are the most common
complaints, and other constitutional symptoms, such
as weight loss, anorexia, and chills, are frequently
reported. Cough, sputum production, and dyspnea
are noted by most patients with pulmonary disease;
pleuritic chest pain may also occur. Signs and symp-
toms specific to extrapulmonary sites of disease, such
as localized lymphadenopathy or meningismus and
headache, are usually experienced by patients found
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to have tuberculosis outside of the lungs. The dura-
tion of signs and symptoms may vary but is usually
at least several weeks, and it may be difficult to dis-
tinguish the symptoms of tuberculosis from those
of Pneumocystis carinii pneumonia or other oppor-
tunistic infections. The abrupt onset of pulmonary
symptoms is unusual in tuberculosis and is more sug-
gestive of pyogenic pneumonia. A chronic wasting
syndrome without any localizing signs or symptoms
may be the only clue to tuberculosis in any patient
with or without HIV infection.
Physical examination is usually nonspecific and
may reveal fever, tachycardia, tachypnea, oral thrush
or hairy leukoplakia, and generalized or regional
lymphadenopathy. Chest examination often shows
localized consolidation, rales, and dullness, although
no abnormalities may be discerned in a number of
patients. Hepatosplenomegaly is frequently found
in HIV-seropositive individuals and is nonspecific
for tuberculosis. The diagnosis of tuberculosis in
HI V-infected patients, as in all groups of patients,
depends upon suspicion by the physician and inclu-
sion of tuberculosis in the differential diagnosis of
opportunistic diseases associated with HIV infection.
Failure to perform appropriate diagnostic tests in
HIV-seropositive patients who present with a pul-
monary or systemic illness will result in underdiag-
nosis and undertreatment of tuberculosis.
How shouldpatientsbeevaluated? Chest radio-
graphs should be performed on all patients with HIV
infection who present with respiratory or constitu-
tional symptoms. The radiographic appearance of
tuberculosis in HIV disease may vary with the de-
gree of immunodeficiency. In patients with more-
advanced HIV disease (e.g., low CD4+ lymphocyte
counts, other opportunistic diseases), the chest ra-
diograph most often has diffuse pulmonary infil-
trates (rv60%), although focal consolidation may
also be present (rv 301J,f0- 40IJ,fo). Cavitary lesions are
uncommon in these patients. Intrathoracic adenopa-
thy may be found in up to 251J,fo of patients with
AIDS-related tuberculosis and should raise the in-
dex of suspicion, because neither R carinii pneumo-
nia nor persistent generalized lymphadenopathy is
associated with mediastinal adenopathy. Pleural ef-
fusion is found in <251J,fo of patients. Several patients
with AIDS who had documented pulmonary tuber-
culosis have been reported to have normal chest ra-
diographs at presentation. In patients with less HIV-
induced immunosuppression, chest radiographs are
more "classic," with upper lobe infiltrates that may
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cavitate (rv45 070 ); lower lung infiltrates without cavi-
tation (rv20%), mediastinal adenopathy (rv20%-
30%), and pleural effusion «10%) are also seen in
this population. The clinical evaluation of pulmo-
nary abnormalities in patients with HIV infection
has been recently reviewed [14]. Tuberculosis should
be included in the differential diagnosis of all pul-
monary disease processes and abnormalities in such
patients, and mycobacterial stains and cultures
should be routinely performed on all diagnostic spec-
imens obtained during the evaluation. For example,
specimens of induced sputum should be stained for
acid-fast bacilli and cultured for mycobacteria in ad-
dition to being stained for P. carinii. Similarly, bron-
choalveolar lavage and transbronchial biopsy spec-
imens should also be stained and cultured for
mycobacteria. Approximately 50% of patients with
pulmonary tuberculosis that occurs earlier in HIV
infection have positive acid-fast smears, whereas up
to 75% of patients with more-advanced HIV disease
will have positive smears. Because culture results may
often be delayed, a positive acid-fast smear should
be presumed to be M tuberculosis, and therapy
should be initiated while awaiting culture confirma-
tion. Patients with a clinical presentation suggestive
of tuberculosis who have negative acid-fast smears
should be empirically treated for tuberculosis until
culture results are available. Use of the BACTEC®
culture system (Johnston Laboratories, Towson,Md)
may considerably accelerate the recovery and iden-
tification of mycobacteria.
Tuberculin skin testing with 5 tuberculin units
(TV) of PPD (purified protein derivative) should be
performed in all HIV-infected patients with sus-
pected tuberculosis. Although many patients with
advanced HIV infection may be anergic, one-third
to one-half of patients with AIDS and tuberculosis
have a >10-mm reaction to PPD. Fifty percent to
80% of HIV-seropositive patients with tuberculosis
but without AIDS react to PPD. In patients with
HIV infection and suspected tuberculosis, a >5-mm
reaction to PPD should be considered indicative of
tuberculous infection. Serological tests, such as an
enzyme immunoassay for antibodies to PPD, show
some promise in diagnosing tuberculous infection
in both immunocompetent and immunodeficient pa-
tients, but these tests are not routinely available.
Extrapulmonary tuberculosis may be present alone
or in addition to pulmonary tuberculosis in patients
with HIV infection. The most common sites involved
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are lymph nodes, blood and bone marrow, urinary
tract, liver, and CNS. When clinical findings or lab-
oratory studies suggest disease at an extrapulmonary
site,aspiration or biopsy of the involvedorgan should
be done and acid-fast smears and mycobacterial cul-
tures performed. Fine-needle aspiration of lymph
nodes is an acceptable alternative to biopsy when
peripheral adenopathy is present. Mediastinal ade-
nopathy can be approached by transbronchial nee-
dle aspiration or mediastinoscopy. Pleural effusion
should be aspirated, and pleural fluid should be
evaluated for cell count and chemistry values as well
as stained and cultured for pyogenic bacteria and
mycobacteria. A closed pleural biopsy may be neces-
sary to diagnose tuberculous pleurisy. CNS disease
can produce ring-enhancing lesions on computed
tomographic scans; a biopsy should be performed
if there is no response to empiric treatment of toxo-
plasmosis. The diagnosis of tuberculosis at an ex-
trapulmonary site should prompt evaluation for pul-
monary involvement by using chest radiographs and
sputum induction for mycobacterial studies.
How should HIV-associated tuberculosis be
treated? Standard antituberculosis drugs are ex-
tremely effective for treating tuberculosis in patients
with HIV infection. Most M tuberculosis isolates
from patients with AIDS are susceptible to the first-
line agents. The recommended regimen for treating
tuberculosis in HIV-infected adult patients is isonia-
zid (300 mg/d), rifampin (600 mg/d; 450 mg/d for
persons weighing <50 kg), and pyrazinamide (20-30
mg/kg per day). Ethambutol (15-25 mg/kg per day)
may also be used if isoniazid resistance is suspected.
Pyrazinamide and ethambutol should be discon-
tinued after two months of therapy if the isolate is
isoniazid susceptible, whereas isoniazid and rifam-
pin are given for a total of six to nine months. Isonia-
zid and rifampin alone given for nine to 12 months
is also an acceptable regimen. The CDC and the
American Thoracic Society recommend that treat-
ment be given for at least six months beyond con-
version of sputum cultures to negative in patients
with HIV infection and pulmonary tuberculosis [15].
Patients not treated with isoniazid or rifampin
should receive at least 18 mo of therapy. Extrapul-
monary disease can also be treated with standard reg-
imens, including isoniazid and rifampin, and ther-
apy should be continued for at least nine to 12
months. There are anecdotal reports of meningeal
or CNS infections that fail to respond or that prog-
AIDS Commentary
ress during antituberculosis therapy. Addition of
second-line agents such as ethionomide or cycloser-
ine may be necessary in such situations.
Clinical experience in treating HIV-associated
tuberculosis with standard short-course chemother-
apy suggests that the response is very favorable, usu-
ally resulting in rapid resolution of symptoms, clear-
ing of radiographic abnormalities, and sterilization
of sputum cultures at the same rate as in HIV-sero-
negative patients [8]. Nevertheless, the appropriate
duration of antituberculosis therapy remains con-
troversial, with some authorities arguing for lifelong
treatment with isoniazid after the completion of
acute therapy with multiple agents. The CDC and
the American Thoracic Society currently recommend
treatment for at least six months after conversion
of cultures to negative [15]. Clinical trials address-
ing the value of lifelong treatment are being planned
but may be difficult to perform because of the large
sample sizes required and competing mortality from
other AIDS-related illnesses. At the San Francisco
Department of Health Tuberculosis Clinic, 71 pa-
tients with AIDS have been treated with short-course
chemotherapy (six to nine months) without main-
tenance therapy; only two patients (one of whom was
noncompliant) had a relapse after antituberculosis
drug therapy was discontinued (G. F. Schecter, per-
sonal communication). Another patient had progres-
sive disease with CNS dissemination while receiv-
ing therapy for an isoniazid-resistant infection.
Patients who are noncompliant or who fail to
complete a full course of therapy are, however, at
increased risk for relapsing, and supervised therapy
should be given to individuals who are considered
to be unreliable or who are unable to manage their
medications because of eNS dysfunction or other
impairment. Patients should have follow-up chest
radiographs and sputum cultures at the completion
of treatment and again six months later. Patients
with advanced HIV disease may have more-adverse
reactions to antituberculosis agents, although this
is not the case for HIV-infected patients who have
tuberculosis but do not have AIDS [4, 8].
Although tuberculosis in HIV-seropositive pa-
tients can be easily managed with appropriate anti-
biotics, other opportunistic infections may supervene
during or after therapy. A patient who appears to
be failing or relapsing may have R cariniipneumo-
nia or disease caused by another pathogen and
should be thoroughly evaluated. The cause of death
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in patients with AIDS and tuberculosis is almost al-
ways another opportunistic infection rather than
M. tuberculosis.
Should preventive therapy be given to PPD-
positive patients with HIV infection? The risk of
developing tuberculosis for a person with HIV in-
fection is substantial. Consequently, chemoprophyl-
axis is recommended for any HIV-seropositive in-
dividual who has a significant reaction to 5 TV of
intradermal PPD [15]. Persons with a documented
history of a positive tuberculin skin test should also
receive preventive therapy. Tuberculin skin testing
should be performed on HIV-infected patients when
they are diagnosed as seropositive, particularly in pa-
tients from populations with an increased risk of
prior M. tuberculosis infection. Although it is pos-
sible that some infected patients will be anergic, data
from HlV-seropositive individuals with tuberculo-
sis cited above suggest that many, if not most, pa-
tients will react to PPD. HIV serological testing
should be considered for patients found to have a
positive tuberculin test, particularly for individuals
who might not otherwise receive preventive therapy
(e.g., >35 y old). Patients with a positive skin test
should have a chest radiograph to evaluate the pres-
ence of active disease; some clinicians would recom-
mend sputum cultures in all patients regardless of
the appearance of the chest radiograph, although the
likelihood of a positive culture from an asymptom-
atic person is very low.
Isoniazid (300 mg/d) is the preferred agent for pro-
phylaxis, except in individuals in close contact with
a patient with disease that is caused by an isoniazid-
resistant organism. The optimal duration of preven-
tive therapy is not known. Although isoniazid should
be administered for at least six to 12 months, some
clinicians would favor lifelong chemoprophylaxis in
patients with HIV infection because of the inevita-
bility of progressive deterioration of cellular immune
function in this population. Currently, there are no
reliable data upon which to base a decision, although
we are not aware of reports of failure of preventive
therapy given for six to 12 months.
Contact tracing is an essential component of
tuberculosis control programs and is especially im-
portant for HIV-associated cases. Close contacts of
cases should be evaluated with a tuberculin skin test.
If an independent risk for HIV infection is present,
HIV antibody testing should also be offered. Con-
tact tracing for HIV-seropositive patients with a sig-
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nificant reaction to PPD may also be useful in iden-
tifying untreated individuals with tuberculosis.
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